CSIMarket Company Name, Ticker, Customers, else..
 
Altamira Therapeutics Ltd   (NASDAQ: CYTO)
Other Ticker:  
 
 
Price: $0.3000 $0.00 0.000%
Day's High: $0.3 Week Perf: -26.9 %
Day's Low: $ 0.30 30 Day Perf: -34.12 %
Volume (M): 724 52 Wk High: $ 2.49
Volume (M$): $ 217 52 Wk Avg: $1.03
Open: $0.42 52 Wk Low: $0.30



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 32
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Altamira Therapeutics Ltd
Altamira Therapeutics Ltd is a biotechnology company focused on the development and commercialization of innovative therapies for neurodegenerative diseases. The company's primary focus is on Parkinson's disease and other related movement disorders. Altamira Therapeutics aims to provide patients with effective treatments that alleviate their symptoms and improve their quality of life. The company utilizes advanced technologies and scientific expertise to discover and develop novel therapies that target the underlying causes of neurodegenerative diseases. Altamira Therapeutics is committed to making a meaningful impact in the field of neurology and improving the lives of patients suffering from these debilitating conditions.


   Company Address: Clarendon House Hamilton 0
   Company Phone Number: 295 59 50   Stock Exchange / Ticker: NASDAQ CYTO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -5.03%    
AZN   -4.97%    
JNJ   -0.8%    
NVS   -2.71%    
PFE   -3.74%    
SNY   -5.69%    
• View Complete Report
   



Announcement

Altamira Therapeutics Expands Bentrio Distribution, Reinforcing Commitment to Allergy Treatment in Scandinavia

Published Fri, Aug 23 2024 1:01 PM UTC

Abstract: Altamira Therapeutics Ltd. is making significant strides in expanding its footprint in the Scandinavian pharmaceutical market with the extension of its distribution agreement for Bentrio, a nasal spray designed for the prevention and treatment of allergic rhinitis. This article outlines the context and potential implications of this expansion, as well as the comp...
Announcement

Bentrio Nasal Spray A Game Changer for Athletes Battling Allergies

Published Fri, Aug 16 2024 1:01 PM UTC

In an exciting development for athletes and sports enthusiasts, Altamira Therapeutics Ltd. has recently announced the successful testing of its Bentrio nasal spray, a preservative-free and drug-free solution for allergic rhinitis. This significant news, revealed on August 16, 2024, confirms that Bentrio is free from over 230 substances prohibited by the World Anti-Doping Age...
Clinical Study

Altamira Therapeutics Utilizes Social Media Channels to Share Positive Results of Nasal Spray Trial for Seasonal Allergic Rhinitis

Published Thu, May 23 2024 12:47 PM UTC

Altamira Therapeutics Announces Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis via Top Allergy Journal s Social Media ChannelsIn a recent announcement, Altamira Therapeutics Ltd. revealed the dissemination of positive results from the NASAR clinical trial with Bentrio nasal spray in seasonal allergic rhinitis (SAR) through the social media channels of Alle...
Partnership

Altamira Therapeutics and Univercells Group Collaborate to Uphold mRNA Vaccine Delivery

Published Mon, Mar 25 2024 12:47 PM UTC

Altamira Therapeutics Joins Forces with Univercells Group to Advance Nanoparticle-Delivered mRNA VaccinesHAMILTON, BERMUDA, March 25, 2024 - Altamira Therapeutics Ltd. (Altamira) (Nasdaq:CYTO), a leading provider of nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, has announced a promising collaboration with Univercells Group (Univercells). T...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com